83
Views
3
CrossRef citations to date
0
Altmetric
Letter to the Editor

Biosimilars and safety issues

, , , , &
Pages 656-658 | Received 12 Nov 2008, Accepted 26 Dec 2008, Published online: 01 Jul 2009

References

  • Pavlou A K, Reichert J M. Recombinant protein therapeutics – success rates, market trends and values to 2010. Nat Biotechnol 2004; 22: 1513–1519
  • Biotechnology Industry organization, Website [online] Available from URL www.bio.org; accessed 26 November 2007
  • Schellekens H. When biotech proteins go off-patent. Trends Biotechnol 2004; 22: 406–410
  • Crommelin D, Storm G, Verrijk R, de Leede L, Jiskoot W, Hennink W E. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003; 266: 3–16
  • Ronco C. Biosimilars: how similar are they/. Int J Artif Organs 2005; 28: 552–553
  • Kuhlmann M K, Goldsmith D, Covic A. Biosimilars. Current status. Int J Pharm Med 2007; 21: 199–206
  • Sharma B. Immunogenicity of therapeutic proteins. Part 2: impact of container closures. Biotechnol Adv 2007; 25: 318–324
  • European Parliament and Council of the European Union. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community Code relating to medicinal products for human use. Off J Eur Union 2004; 136: 34–57
  • European Agency for the Evaluation of Medicinal Products, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal product, Note for guidance on the investigation of bioavailability and bioequivalence. London, CHMP/437/04, 30 October 2005
  • Crommelin D, Bermejo T, Bissig M, Damiaans J, Krämer I, Rambourg P, et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. Eur J Hosp Pharm Sci 2005; 11: 11–17
  • Casadevall, Eckardt K-U, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005; 16: S67–S69
  • European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence. London, CPMP/EWP/QWP/1401/98, 26 July 2001
  • European Medicines Agency. BINOCRIT, European Public Assessment Reports (EPAR), EMEA/H/C/725 July 2007. Available online: http://www.emea.europa.eu/humandocs/Humans/EPAR/binocrit/binocrit.htm
  • European Medicines Agency. HEXAL, European Public Assessment Reports (EPAR), EMEA/H/C/726 July 2007. Available online: http://www.emea.europa.eu/humandocs/Humans/EPAR/epoetinalfahexal/epoetinalfahexal.htm
  • European Medicines Agency. ABSEAMED, European Public Assessment Reports (EPAR), EMEA/H/C/727 July 2007. Available online: http://www.emea.europa.eu/humandocs/Humans/EPAR/abseamed/abseamed.htm

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.